Lyell Immunopharma, Inc. (LYEL) AI Dilution Summary

Cash was $227,998,000 at the 2026-06-30 balance-sheet date, against estimated monthly burn of $12,072,000. The funding channel in use is the ATM program with TD Securities (USA) LLC (formerly Cowen and Company, LLC), authorised to $150,000,000, through which 65,092 shares were sold since the program began, through 2026-06-30; sales after 2026-06-30 are not yet reported. The most recent capital raised was ATM sales through 2026-06-30.